| __timestamp | Amphastar Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 18516000 |
| Thursday, January 1, 2015 | 37065000 | 34140000 |
| Friday, January 1, 2016 | 41199000 | 51872000 |
| Sunday, January 1, 2017 | 43415000 | 71772000 |
| Monday, January 1, 2018 | 57564000 | 97501000 |
| Tuesday, January 1, 2019 | 68853000 | 118590000 |
| Wednesday, January 1, 2020 | 67229000 | 169802000 |
| Friday, January 1, 2021 | 60932000 | 192507000 |
| Saturday, January 1, 2022 | 74771000 | 199563000 |
| Sunday, January 1, 2023 | 73741000 | 253598000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xencor, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Xencor's R&D expenses surged by over 1,270%, peaking at approximately $254 million in 2023. This aggressive investment reflects Xencor's commitment to pioneering new therapies. In contrast, Amphastar's R&D spending grew by a more modest 160%, reaching around $74 million in the same year. This difference highlights Amphastar's steady, yet cautious approach to innovation. The data underscores a broader trend in the pharmaceutical industry: while some companies opt for rapid expansion in R&D to capture market share, others prefer a more measured pace, balancing innovation with financial prudence. As the industry evolves, these strategies will shape the future of healthcare breakthroughs.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Xencor, Inc.
Research and Development Expenses Breakdown: Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
R&D Insights: How Rhythm Pharmaceuticals, Inc. and Xencor, Inc. Allocate Funds
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Xencor, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Evotec SE vs Xencor, Inc.